Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of bimekizumab in moderate to severe hidradenitis suppurativa
MOH_2020-08-17_009242Phase 3Not yet recruiting
- Sponsor
- UCB
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in hidradenitis suppurativa (HS) (4 arms), sponsored by UCB. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2020-08-17_009242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-17_009242.